Journal of Clinical Oncology
Articles in this Issue
Prospective validation of dynamic circulating tumor DNA (ctDNA)–based MRD for predicting progression-free survival and treatment benefit in oral cancer.
e18090 Background: Effective disease control in oral cancer heavily relies on the accurate identification and management of minimal residual disease (MRD)...
MicroRNA-based biomarkers of outcome in soft tissue sarcoma treated with hypofractionated preoperative radiation therapy.
11538 Background: Soft tissue sarcomas (STS) are rare, aggressive malignancies with high variability in response to radiation therapy (RT). Our previous r...
Phase I/II study of maintenance therapy with metformin and temozolomide for newly diagnosed glioblastoma.
2051 Background: Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis. A potential strategy for overcoming therapeutic resistance i...
Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.
7515 Background: In DREAMM-8 (NCT04484623), BPd demonstrated a statistically significant, clinically meaningful benefit to progression-free survival (PFS)...
Phase III study on atezolizumab versus placebo in adjuvant therapy of pleural mesothelioma patients after pleurectomy/decortication: Preliminary results of the AtezoMeso study.
8087 Background: AtezoMeso Study is a multicentric double-blind, placebo-controlled, Phase III trial, that aims to evaluation the efficacy of adjuvant ate...
Temporal trends in myeloproliferative neoplasms–related mortality in the United States over the last three decades: An analysis of the Global Burden of Disease database.
e18601 Background: Myeloproliferative neoplasms (MPNs) are a group of hematologic malignancies associated with substantial morbidity and mortality. Unders...
Mortality trends of lower respiratory tract neoplasms among older adults with history of tobacco use in the United States, 1999-2020.
e22548 Background: Lower respiratory tract neoplasms (LRTN) are a leading cause of death among the elderly in the U.S. Given the established link between...
Individual participant data meta-analysis comparing neoadjuvant to perioperative chemoimmunotherapy in early-stage non-small cell lung cancer according to PD-L1 status.
e20035 Background: Neoadjuvant and perioperative chemo-immunotherapy are two standard-of-care treatment options for patients with early-stage Non-Small Ce...
GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.
10557 Background: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of breast cancer. Glucagon-like peptide 1 receptor agonists (GLP-1R...
Multi-center investigation of an early detection model utilizing cfDNA fragmentomics for breast cancer screening.
e15033 Background: Breast cancer is the most prevalent malignancy among women globally, and early detection significantly improve the prognosis of BC pati...
Long-term outcomes following melanoma metastasectomy categorized by response to immune checkpoint inhibitor (ICI) therapy.
9563 Background: Patients undergoing surgical resection of Stage III/IV melanoma after response to ICIs show favorable survival, particularly with patholo...
Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy.
8579 Background: Real-time monitoring is critical for tailoring treatments to individual patient responses in clinical oncology. Plasma proteomics offers...
A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer.
TPS5625 Background: All antibodies currently approved for cancer therapy are monoclonal IgGs. MOv18 IgE is a first-in-class therapeutic IgE antibody to ha...
A populational change in prognosis of patients diagnosed with locally advanced melanoma: Last glimpse before the introduction of adjuvant treatment in stage IIB/C.
e21575 Background: The treatment of early-stage melanoma is rapidly changing. Recent advancements include neoadjuvant treatment in stage III clinically de...
Utilization and timeliness of next-generation sequencing testing for patients with resected or metastatic non-small cell lung cancer: A real-world analysis.
11101 Background: Comprehensive next-generation sequencing (NGS) is an evidence-based molecular testing modality used to identify actionable oncogenic dri...
Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.
9502 Background: Neoadjuvant immune checkpoint therapy has shown improvement in event-free survival outcomes in patients w...
QUILT 3.076 phase 1 study of memory-like cytokine-enriched natural killer (M-CENK) cells plus N-803 in locally advanced or metastatic solid tumors.
TPS2680 Background: Lymphopenia and low levels of natural killer (NK) cells may contribute to poor prognosis and response to therapy in cancer patients, c...
Hippocampal-avoidance whole-brain radiotherapy with dose escalation on metastases: A prospective randomized trial (HIPPORAD).
2038 Background: The HIPPORAD trial aimed to evaluate a new method of whole brain radiation therapy (WBRT) with simultaneous integrated boost (SIB) to the...
Are we casting the net wide enough? Applying the proposed lung cancer screening criteria in single centre lung cancer resections.
8066 Background: The Australian National Lung Cancer Screening Program (NLCSP) commences in July 2025. Thoracic surgery is a key treatment option in scree...
Impact of great circle distance on breast cancer survival in NCDB.
e13833 Background: Timeliness of breast cancer (BC) care, defined as initiation of treatment within 60 days of diagnosis, has a significant impact on surv...
Detection of antibody-drug conjugate target expression on tumor-derived extracellular vesicles circulating in blood plasma of oncology patients.
e14549 Background: Antibody-drug conjugates (ADCs) are a novel class of biotherapeutics designed to target tumor associated antigens using monoclonal anti...
Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.
e18019 Background: Nasopharyngeal carcinoma (NPC) patients with T4 or N2–3 or lymph node >3cm diseases have a high risk of metastasis. This study aimed...
Immunotherapy combined with hypofractionated radiotherapy and chemotherapy for locally recurrent rectal cancer (TORCH-R): A prospective, single-arm, two-cohort, phase II trial.
3523 Background: To assess whether the integration of PD-1 inhibitor with hypofractionated radiotherapy and chemotherapy t...
Relationships among polyunsaturated fatty acid profiles, immune landscapes, and immunotherapy prognoses in gastric cancer.
e14560 Background: Advanced gastric cancer patients undergoing first-line immunotherapy combined with chemotherapy often experience suboptimal outcomes. T...
Evaluating activation of MAPK signaling as a potential mechanism of acquired resistance to lorlatinib in ALK-rearranged lung cancer.
e20000 Background: The third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib has significantly advanced the clinical management of advanced ALK-...